HOME

EverMed Inc. is a biotech startup founded based on the research of Dr. Yu Fujita of the Department of Respiratory Medicine and Next-Generation Drug Discovery Research at the Jikei University School of Medicine (Tokyo Japan) on the use of extracellular vesicles (EVs) to treat intractable respiratory diseases.

It is estimated that there are more than 1 billion patients worldwide who suffer from respiratory diseases such as lung cancer, asthma, COPD, and interstitial pneumonia. For example, about 2 million people die from lung cancer, about 3.3 million from COPD, and more than 1 million people die each year from various interstitial pneumonias and acute respiratory distress syndrome (ARDS) caused by infectious diseases such as COVID-19. However, there are still insufficient treatments for these respiratory diseases.

To address these unmet medical needs, we are focusing on the use of EVs, a natural homeostatic mechanism in the human body, and are trying to create new treatments that address the root causes of diseases, including the inhibition of cellular aging.